TVRD
Tvardi Therapeutics, Inc.
There isn't enough reported data to score TVRD yet.
TVRD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Strong |
TVRD's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
TVRD PE Valuation
TVRD has no meaningful PE right now: it lost money over the past year.
TVRD Forward outlook
There aren't enough analyst estimates for TVRD to show an outlook.
TVRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.79 | +$14.54 |
| Q1 2026 | -$3.10 | +$26.55 |
| Q4 2025 | -$5.59 | +$41.00 |
| Q3 2025 | -$9.64 | +$53.72 |
| Q2 2025 | -$17.33 | +$56.47 |
| Q1 2025 | -$29.65 | +$51.71 |
| Q4 2024 | -$46.59 | +$32.25 |
| Q3 2024 | -$63.36 | +$14.04 |
TVRD is still losing money, but far less than before: $2.79 per share over the past year, against $91.80 at its worst in early 2020.
TVRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $2.6M | +20% |
| Q4 2024 | $1.5M | -52% |
| Q3 2024 | $2.6M | -47% |
| Q2 2024 | $991K | -86% |
| Q1 2024 | $2.1M | -65% |
| Q4 2023 | $3M | -7.9% |
| Q3 2023 | $4.9M | -55% |
| Q2 2023 | $6.9M | -70% |
TVRD's revenue is recovering but still below its 2020 peak: $3M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -93% | +1297 points |
| Q4 2024 | -373% | +713 points |
| Q3 2024 | -234% | +360 points |
| Q2 2024 | -1746% | -1280 points |
| Q1 2024 | -1390% | -941 points |
| Q4 2023 | -1085% | -125 points |
| Q3 2023 | -594% | -373 points |
| Q2 2023 | -466% | -447 points |
TVRD's operating margin was −93% last quarter, up 1297 points from the same quarter a year ago.
TVRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | -$363K |
| Q4 2025 | -$5.7M | -$1.6M |
| Q3 2025 | -$4.3M | +$9.7M |
| Q2 2025 | -$8.9M | +$3.8M |
| Q4 2024 | -$4M | +$15.4M |
| Q4 2023 | -$19.4M | +$4.1M |
| Q2 2022 | -$4.5M | +$16.5M |
| Q1 2022 | -$25.6M | -$1.8M |
TVRD has burned cash in almost every quarter: −$25M over the past year, against −$40M the year before.
TVRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +11% | +926K shares |
| 3 years | +525% | +7.9M shares |
| 5 years | +575% | +8M shares |
| Available history | +659% | +8.1M shares |
TVRD has 9M diluted shares, up 11% from a year ago.
TVRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -1.0x | Net Cash |
| Q2 2021 | -3.2x | Net Cash |
| Q1 2021 | -1.9x | Net Cash |
| Q4 2020 | -5.7x | Net Cash |
TVRD has more cash than debt.
TVRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 15.1 | Oversold |
TVRD's weekly RSI is 36 (neutral) and its Stochastic is 15 (oversold).
TVRD PE vs Healthcare Sector
TVRD has no meaningful PE right now: it lost money over the past year.
TVRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.04 | 12% above |
| 20 week MA | $1.71 | 32% below |
| 50 week MA | $2.86 | 59% below |
TVRD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 50-week average.
TVRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $14.7 | $4.14 | -72% |
| 2026 YTD | $4.14 | $1.16 | -72% |
TVRD has finished every year since 2025 lower, and it's down 72% so far in 2026.